Sign inJoin waitlistJoin the waitlist

KD

Kathleen Dorritie

Physician · Upmc

Credentials: · · · ·

History

Upmc
Present

Internal Medicine
2007–2010
Hematology and Medical Oncology
UPMC Medical Education
2007–2010
Doctor of Medicine
2003–2007

Research

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
New England Journal of Medicine · 2023 · 409 citations
Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study
The Lancet · 2023 · 179 citations
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 2023 · 178 citations

Alison Sehgal
19 papers
Annie Im
19 papers
MA
Mounzer Agha
19 papers
AR
Anastasios Raptis
18 papers
JH
Jing-Zhou Hou
18 papers
MB
Michael Boyiadzis
17 papers
RF
Rafic Farah
17 papers
Robert Redner
13 papers
SL
Seah Lim
10 papers
Konstantinos Lontos
8 papers · 2 as a fellow
JR
James Rossetti
6 papers
Stanley Marks
5 papers

Clinical trials

Mezigdomide Plus Ixazomib and Dexamethasone for Relapsed and Refractory Multiple Myeloma
Principal investigator · Withdrawn · Phase 1, Phase 2
Kathleen Dorritie
2023–2026
Stem Cell Transplant in Patients With Severe Sickle Cell Disease
Principal investigator · Terminated · Early phase 1
Kathleen Dorritie
2018–2022
Testing the Effect of Teclistamab on Recurrent Plasmablastic Lymphoma
Site PI · Recruiting · Phase 1
National Cancer Institute (NCI)
2027